Dip in 2nd-qtr 2016 generic sales does not knock confidence during Teva's 'year of transition'

4 August 2016

Bosses at Teva Pharmaceutical Industries (NYSE: TEVA) remain confident in its ability to deliver multi-year growth despite a slight dip in sales in its generics business in this year’s second quarter compared to the same period of 2015.

It comes in the week that the Israeli company, which was already the world’s leading seller of generic medicines, completed the $40.5 billion deal to buy the generics arm of Ireland-incorporated Allergan (NYSE: AGN) and agreed to buy the same company’s Anda subsidiary.

Erez Vigodman, Teva’s chief executive, called 2016 a “transition year” as he presented the latest quarterly results, and he remains confident that the company’s plans for 1,500 generic launches globally in 2017 and expanded pipeline will deliver growth in the longer term.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK